Angiolipo: Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting

Sponsor
University Hospital, Caen (Other)
Overall Status
Unknown status
CT.gov ID
NCT01932021
Collaborator
(none)
10
1
1
20
0.5

Study Details

Study Description

Brief Summary

The hypertensive leg ulcer is a very painful leg related to acute skin microangiopathy. It occurs in patients older than 60 years followed for hypertension. Clinical diagnosis requires eliminating other causes arterial ulcers, cryoglobulinemia, thrombophilia, cholesterol crystal emboli, vasculitis associated with hepatitis C, myeloproliferative disorders and ulcers associated with the Hydrea ® outlet.

There is no treatment of the ulcer because conventional treatments are ineffective. The pain has subsided by analgesics III. Other treatments are not effective outside skin grafts to be repeated because they necrotic regularly. In a prospective uncontrolled study, 11 patients healed through autohemotherapy.

Ineffective treatment of this painful condition and efficiency of these cells to the damaged tissue, due to the secretion of many bioactive molecules, led us to propose subcutaneous injections of autologous fat to change the wound bed, promote healing and eliminate pain. This treatment should help to avoid long-term hospitalization (about 15 days) that can lead to physical and psychological degradation of these elderly patients.

The investigators propose an open clinical study of 10 patients with a single-center recruitment (CHU Caen). The study took place over a period of 18 months with a 12-month recruitment and follow-up of 6 months for each patient.

The purpose of this study was to evaluate the one hand, tolerance, in terms of pain and side effects, and, on the other hand, the effectiveness of this therapeutic approach, in terms of healing of the ulcer assuming a decrease in the size of the estimated at least 40% at 3 months wound. The measure of effectiveness will also focus on the changing appearance of the wound, including the relative areas of fibrin, necrosis and budding. These efficiency measures (area ratio) will be done through a computer program (CANVAS ®) on photographs taken at each assessment time.

Eventually, if this study was to demonstrate the effectiveness of this treatment lipofilling, it would be possible to perform a multicenter study on a large number of patients to demonstrate the effectiveness, in terms of wound healing that the pain it causes and offer a shorter hospital stay, and in parallel, this approach should improve the pathophysiology of ulceration (translational research).

Condition or Disease Intervention/Treatment Phase
  • Procedure: adipose tissue grafting
N/A

Detailed Description

The objective of this study was to evaluate the one hand, tolerance, in terms of pain and side effects, and secondly, the effectiveness of this therapeutic approach, in terms of healing of the ulcer assuming a decrease in the size of the estimated at least 40% at 3 months wound. The objective also covers the measurement of changes in the appearance of the wound, with an expected decrease of relative areas of fibrin and necrosis. The percentage of wound healing and wound area was measured at each visit, a curve will be performed for each patient to assess the speed of healing and the appearance of the wound will be notified.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
10 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting
Study Start Date :
Apr 1, 2013
Anticipated Primary Completion Date :
Apr 1, 2014
Anticipated Study Completion Date :
Dec 1, 2014

Arms and Interventions

Arm Intervention/Treatment
Experimental: adipose tissue grafting

Procedure: adipose tissue grafting

Outcome Measures

Primary Outcome Measures

  1. Treatment of hypertensive leg ulcer by adipose tissue grafting [one year]

    The objective of this study is to evaluate pain

Secondary Outcome Measures

  1. treatment of angiodermatitis necrotitis by lipofilling [one year]

    Other objectives are to evaluate the tolerance, in terms of pain and side effects, and secondly, the effectiveness of this therapeutic approach, in terms of healing of the ulcer assuming a decrease in the size of the estimated at least 40% at 3 months wound. The objective also covers the measurement of changes in the appearance of the wound, with an expected decrease of relative areas of fibrin and necrosis. The percentage of wound healing and wound area was measured at each visit, a curve will be performed for each patient to assess the speed of healing and the appearance of the wound will be notified.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients over 18 years with a necrotic ulcer or angiodermatitis Martorell.

  • Recipient of the system of social security.

  • Ulceration sudden onset peripheral Livedoid border, on superficial leg without bone or tendon exposure.

  • IPS Index (systolic pressure)> 0.8 with pedal pulses.

  • Wound area less than 300 cm2 surface measurement with Canvas ® software from a photograph of the wound next to which there is a calibration strip.

  • Patients with hypertension.

  • Patient was informed of the study and having signed an informed consent.

Exclusion Criteria:
  • Severe distal arteritis (arteritis of large arteries).

  • Histological vasculitis.

  • Collagen (THE BY, scleroderma).

  • Blood Pathology: Cryoglobulinemia, Polycythemia.

  • Hepatitis A, B and C, HIV and syphilis infection

  • Thrombophilia (search for markers during the initial assessment in patients with a history of phlebitis or miscarriage).

  • Hyperthyroidism.

  • Patient treated with Hydrea (favoring the occurrence of ulcers).

  • Patient participating in another study to treat the wound concerned.

  • Topics minors, pregnant women, persons deprived of liberty, adults under legal protection unable to consent.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Hospital, Caen Caen France 14 000

Sponsors and Collaborators

  • University Hospital, Caen

Investigators

  • Principal Investigator: Anne Dompmartin, MD, University Hospital, Caen

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
University Hospital, Caen
ClinicalTrials.gov Identifier:
NCT01932021
Other Study ID Numbers:
  • 2012-A01613-40
First Posted:
Aug 30, 2013
Last Update Posted:
Apr 9, 2014
Last Verified:
Apr 1, 2014
Keywords provided by University Hospital, Caen
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 9, 2014